The national budget proposal for the 2019 fiscal year includes a request for $13 billion in funding for opioid treatment and related services. This linked Newsweek article states that $3 billion would be allocated in 2018 and another $10 billion in 2019.
Many opioid treatment programs across the country are currently able to add patient slots when additional funding is made available. The opioid crisis has flooded many clinics that are already at maximum census due to limited State and Medicaid funding.
A number of private pay clinics have opened in recent years as the need for medication-assisted treatment increased. If a substantial allocation of government funds becomes available, opioid treatment services will finally come into sharp national focus as scores of people finally obtain the help they need to stabilize and to recover.
In treating opioid addiction, research has shown that traditional abstinence-based programs which do not utilize medication assistance have a failure rate of 90%. Medication-assistance is a critical factor in helping opioid addicted people move into sustained recovery. The proposed $13 billion earmarked for opioid treatment services can make a huge difference all across the U.S. Methadone or buprenorphine (suboxone) coupled with counseling and drug testing comprise the gold standard of care in treating opioid addiction.
Posted in Addiction Recovery, Buprenorphine, Drug Treatment, Methadone, Methadone Benefits, Methadone Clinics, Methadone Maintenance, Methadone News, Opiate Treatment, Suboxone, Suboxone Doctors
Right Path provide a variety of opioid, alcohol, and other drug addiction treatment services through their various outpatient programs located in Virginia and North Carolina.
The organization utilizes Medication-Assisted Treatment (MAT) for opioid use disorders, and they provide confidential consultation to individuals who are trying to determine the best of course of treatment for dealing with their addiction issues. Right Path are equipped to now provide the new Probuphine implant that utilizes time-released buprenorphine to alleviate opioid withdrawal symptoms as individuals pursue a solid, long-term personal recovery.
Right Path endorse the benefits of 12 Step philosophy while also incorporating a strong medical component in their opioid recovery program due to the statistically high percentage of opioid addicted people who will ultimately relapse without medication-assisted support.
Read more about Right Path’s services and counseling approach at the link above.
Posted in Addiction Counseling, Addiction Recovery, Buprenorphine, Methadone, Opiate Treatment, Recovery, Suboxone, Suboxone Clinics, Suboxone Doctors, Suboxone Physicians
Tagged outpatient treatment, Right Path
Many state-funded addiction treatment services have undergone gradual cuts during the last 15 years. With the rising opioid addiction crisis in America, better access to opioid treatment is definitely needed.
There are a number of private clinics and outpatient treatment centers opening their doors in most every state. These private clinics are meeting a need for services that are often absent in more remote areas of the country.
Some new opioid treatment providers are smaller, independent methadone clinics while others are part of a larger network such as those owned by Acadia Healthcare, Behavioral Health Group (BHG), or Colonial Management Group.
They all have one thing in common, and it is that they provide their patients with medication-assisted treatment (MAT). MAT is scientifically proven to be more effective than other forms of abstinence-based treatment.
Medication assistance typically utilizes methadone or buprenorphine-based products to alleviate a patient’s chronic opioid withdrawal. Without medication-assistance, patients often face either a detox admission or they struggle on in a daily effort to secure opiates so as to prevent the return of withdrawal sickness.
People ready for opioid treatment may find that their local methadone clinic is full, or that their nearest clinic is just too far away to access on a daily basis. For some patients, suboxone/buprenorphine may be the best solution since a prescription can be obtained for several weeks of medication before a return visit is required.
Access to treatment is currently on the radar of national healthcare officials and government legislators, many of whom have received numerous letters and calls from families requesting more funding for treatment, and better access. Media coverage has also been much improved during the past 3 years in part due to the widespread opioid crisis and its broad impact.
Supporting local opioid addiction treatment services is important for every community. It ultimately saves lives, reduces crime, and promotes recovery so that addicted patients can work and function.
The U.S. House of Representatives just passed a sweeping reform, called the 21st Century Cures Act, that will infuse $1 billion in new funding earmarked for opioid treatment and prevention services.
It has taken several years of alarming statistics on the national opioid epidemic, but Congress has responded. This USA Today article provides an overview of the numbers. In addition to the $1 billion for opioid services will be another $4.8 billion for cutting-edge research around treating Alzheimers, cancer, traumatic brain injury, and other medical issues.
The bill received enormous bipartisan support and passed 392-to-26. In 2016, death by drug overdose surpassed death by car crashes and gun fatalities. The public outcry for government intervention has been steady. With so many families having been affected by addiction issues, the new funding allowance should open doors for opioid treatment particularly in rural areas where opioid services have been severely lacking.
Methadone remains the #1 medication-assisted treatment option. Buprenorphine medications are; however, making a big impact in the treatment field with a wide variety of buprenorphine-based formulations coming to market. In addition to the familiar suboxone film, are probuphine (a buprenorphine implant), subutex (an uncoated buprenorphine tablet), and bunavail.
Posted in Addiction Treatment, Buprenorphine, Drug Treatment, Medication Assisted Treatment, Methadone, Methadone Clinics, Methadone Maintenance, Naloxone, Naltrexone, Opiate Treatment, Suboxone
Tagged drug legislation, drug treatment funding, opioid treatment
The FDA has approved a new implantable drug called Probuphine. Probuphine contains the partial opioid agonist, buprenorphine, which is used to suppress the opioid withdrawal symptoms that interfere with daily life.
The implant is the size of a matchstick and is inserted under the skin in the forearm area. It steadily releases a dose of buprenorphine which has been scientifically proven an effective treatment for eliminating opiate withdrawal symptoms in a number of people physically dependent on opioids.
With heroin and opioid overdose deaths at an all time high in the United States, this new alternative offers one more beneficial path for anyone struggling with opioid relapse and chronic withdrawal. Importantly, Probuphine only treats the physical withdrawal from opioids such that the underlying psychological factors of addiction must still be treated through counseling and other support approaches.
The Wall Street Journal has an extensive article on this new medication and the historically important role of methadone and oral buprenorphine. In the article, Nora Volkow (director of the National Institute on Drug Abuse) is quoted as saying:
Scientific evidence suggests that maintenance treatment with these medications in the context of behavioral treatment and recovery support are more effective in the treatment of opioid-use disorder than short-term detoxification programs aimed at abstinence.
Over 47,000 people died in the U.S. of drug overdoses in 2014. A majority of these were attributed to heroin and prescription painkillers. With continued coverage in the media and ongoing community discussion, more answers and helpful interventions will hopefully see the light of day.
Methadone Information | Suboxone Information